Abstract

Automatic MR imaging segmentation of the prostate provides relevant clinical benefits for prostate cancer evaluation such as calculation of automated PSA density and other critical imaging biomarkers. Further, automated T2-weighted image segmentation of central-transition zone (CZ-TZ), peripheral zone (PZ), and seminal vesicle (SV) can help to evaluate clinically significant cancer following the PI-RADS v2.1 guidelines. Therefore, the main objective of this work was to develop a robust and reproducible CNN-based automatic prostate multi-regional segmentation model using an intercontinental cohort of prostate MRI. A heterogeneous database of 243 T2-weighted prostate studies from 7 countries and 10 machines of 3 different vendors, with the CZ-TZ, PZ, and SV regions manually delineated by two experienced radiologists (ground truth), was used to train (n = 123) and test (n = 120) a U-Net-based model with deep supervision using a cyclical learning rate. The performance of the model was evaluated by means of dice similarity coefficient (DSC), among others. Segmentation results with a DSC above 0.7 were considered accurate. The proposed method obtained a DSC of 0.88 ± 0.01, 0.85 ± 0.02, 0.72 ± 0.02, and 0.72 ± 0.02 for the prostate gland, CZ-TZ, PZ, and SV respectively in the 120 studies of the test set when comparing the predicted segmentations with the ground truth. No statistically significant differences were found in the results obtained between manufacturers or continents. Prostate multi-regional T2-weighted MR images automatic segmentation can be accurately achieved by U-Net like CNN, generalizable in a highly variable clinical environment with different equipment, acquisition configurations, and population. • Deep learning techniques allows the accurate segmentation of the prostate in three different regions on MR T2w images. • Multi-centric database proved the generalization of the CNN model on different institutions across different continents. • CNN models can be used to aid on the diagnosis and follow-up of patients with prostate cancer.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.